Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Dr Perez on the Efficacy and Safety of Frontline Petosemtamab Plus Pembrolizumab in HNSCC

August 8th 2024

Cesar A. Perez, MD, discusses the ongoing investigation of frontline petosemtamab plus pembrolizumab in head and neck squamous cell carcinoma.

IMRT Alone is Non-Inferior to CCRT in Nasopharyngeal Carcinoma

August 6th 2024

Radiotherapy was non-inferior vs chemoradiotherapy in patients with nasopharyngeal carcinoma, and less toxicity was observed with radiotherapy alone.

UV1 Plus Pembrolizumab Fails to Yield Survival Benefit in Metastatic/Recurrent Head and Neck Cancer

August 5th 2024

UV1 plus pembrolizumab did not improve progression-free survival or overall survival in patients with metastatic or recurrent head and neck cancer.

Dr Wong on Challenges Incorporating Checkpoint Inhibitors into Curative-Intent Regimens in HNSCC

July 31st 2024

Deborah J. Wong, MD, PhD, discusses challenges incorporating checkpoint inhibitors into curative-intent approaches for patients with head and neck squamous cell carcinoma.

CHMP Recommends Toripalimab Plus Chemo for Metastatic Nasopharyngeal Carcinoma and Advanced ESCC

July 29th 2024

The EMA’s CHMP has recommended toripalimab plus chemotherapy for metastatic nasopharyngeal carcinoma and advanced esophageal squamous cell carcinoma.

Pembrolizumab Plus Chemo Elicits Responses in Head and Neck Squamous Cell Carcinoma

July 27th 2024

Frontline pembrolizumab, carboplatin, and paclitaxel demonstrated antitumor activity in recurrent or metastatic head and neck squamous cell carcinoma.

Dr Wirth on the Safety of Selpercatinib in RET Fusion+ Thyroid Cancer

July 25th 2024

Lori Wirth, MD, discusses the safety selpercatinib in adult or pediatric patients with advanced or metastatic RET fusion–positive thyroid cancer.

Dr Posner on the Mechanism of Action of Danivatirsen in HNSCC

July 25th 2024

Marshall Posner, MD, discusses the mechanism of action of danvatirsen in recurrent and/or metastatic head and neck squamous cell carcinoma.

FDA Grants Fast Track Designation to Ozuriftamab Vedotin in Recurrent/Metastatic HNSCC

July 23rd 2024

The ROR2-targeted ADC ozuriftamab vedotin has received FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

Autologous TIL Therapy Plus Pembrolizumab Under Exploration in PD-L1–Resistant Advanced HNSCC

July 18th 2024

A phase 1b trial is evaluating the TIL therapy TBio-4101 plus pembrolizumab in PD-(L)1 inhibitor–resistant head and neck squamous cell carcinoma.

Dr Olazagasti on Disparities in Lung Cancer Screening Rates for Hispanic Head and Neck Cancer Survivors

July 18th 2024

Coral Olazagasti, MD, discusses disparities in lung cancer screening rates between Hispanic and non-Hispanic White survivors of head and neck cancer.

Dr Sun on Managing TEAEs of Tisotumab Vedotin in Recurrent/Metastatic HSNCC

July 16th 2024

Lova Sun, MD, MSCE, discussions safety implications observed from part C of the phase 2 innovaTV 207 trial.

Dr Kirtane on the Design of a Phase 1b Trial of Tbio4101 Plus Pembrolizumab in HNSCC

July 15th 2024

Kedar Kirtane, MD, discusses the design of a phase 1b trial evaluating the TIL Tbio-4101 plus pembrolizumab in patients with advanced HNSCC.

Dr Mehra on the Implications of the E3311 Trial in HPV+ Oropharynx Cancer

July 11th 2024

Ranee Mehra, MD, discusses long-term follow-up data from the phase 2 E3311 trial in patients with HPV-associated oropharynx cancer.

First-line Eftilagimod Alpha Plus Pembrolizumab Generates Favorable ORR in PD-L1–Negative HNSCC

July 11th 2024

Frontline eftilagimod alpha plus pembrolizumab was safe and elicited responses in patients with PD-L1–negative head and neck squamous cell carcinoma.

Dr Wirth on Questions About Selpercatinib Use in Advanced RET Fusion+ Thyroid Cancer

July 11th 2024

Lori Wirth, MD, discusses questions about the treatment of patients with RET fusion+ thyroid cancer following the full approval of selpercatinib.

Dr Wirth on the LIBRETTO-001 Trial of Selpercatinib in RET Fusion+ Thyroid Cancer

July 3rd 2024

Lori Wirth, MD, discusses the LIBRETTO-001 trial of selpercatinib for patients with advanced or metastatic RET fusion–positive thyroid cancer.

OncLive’s June Roundup of Key FDA Approvals in Oncology

July 3rd 2024

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

ASTRO Issues Clinical Practice Guideline For Radiation Therapy in HPV-Associated OPSCC

July 3rd 2024

The American Society for Radiation Oncology has released a guideline to characterize the place of radiation therapy in HPV-associated oropharyngeal squamous cell carcinoma.

Revisit Every OncLive On Air Episode From June 2024

July 1st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.